Skip to Main Content

Hello, everyone, and welcome to the middle of the week. Time flies when you are … quarantined? Well, so much in life is a matter of perception, yes? Nonetheless, you have made it this far, so time to celebrate with a delicious cup of stimulation. Our choice today is vanilla caramel cream. One can never be too sweet, after all. Please feel free to join us. Meanwhile, here is the latest menu of tidbits to get you going. Hope your day is productive and safe. And as always, please do keep in touch. …

Heavy hearts soared with news the Moderna (MRNA) Covid-19 vaccine candidate — the frontrunner in the U.S. market — seemed to generate an immune response in Phase 1 trial subjects. Its market cap surged to $29 billion, an astonishing feat for a company that currently sells zero products. But was there good reason for so much enthusiasm? Several vaccine experts told STAT that, based on the information made available by the company, there is really no way to know how impressive — or not — the vaccine may be.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!